Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2014

Open Access 01-12-2014 | Research article

Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review

Authors: Richard J Bright, Jenny Wilkinson, Brendon J Coventry

Published in: BMC Neurology | Issue 1/2014

Login to get access

Abstract

Background

Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more than two months. Many individuals with chronic inflammatory demyelinating polyradiculoneuropathy fail to make a long-term recovery with current treatment regimes. The aim of this study was to prospectively review the literature to determine the effectiveness of therapies for chronic inflammatory demyelinating polyradiculoneuropathy.

Methods

Articles published from January 1990 to December 2012 were searched for studies to treat adults with chronic inflammatory demyelinating polyradiculoneuropathy. Peer-reviewed full-text articles published in English were included.

Results

Nine placebo-controlled double-blinded randomised trials were reviewed to treat subjects with chronic inflammatory demyelinating polyradiculoneuropathy exhibiting various degrees of effectiveness. The most effect treatments were; three randomised controlled trials using intravenous immunoglobulin, a study comparing pulsed dexamethasone and short term prednisolone and rituximab all showed promising results and were well tolerated.

Conclusion

IVIg and corticosteroids remain first line treatments for CIDP. Therapies using monoclonal antibodies, such as Rituximab and Natalizumab offer the most promise for treatment of Chronic inflammatory demyelinating polyradiculoneuropathy however they also need further research, as does the use of stem cell therapy for treating Chronic inflammatory demyelinating polyradiculoneuropathy. Large randomised controlled trials and better patient selection are required to address responsiveness of CIDP patients to conventional treatments to elucidate mechanisms of action and future directions for therapeutic improvement.
Appendix
Available only for authorised users
Literature
1.
Hughes RA, Allen D, Makowska A, Gregson NA: Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2006, 11 (1): 30-46. 10.1111/j.1085-9489.2006.00061.x.CrossRefPubMed
2.
Dalakas MC: Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies. J Peripher Nerv Syst. 2012, 17 (Suppl 2): 34-39.CrossRefPubMed
3.
Dalakas MC: Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011, 7 (9): 507-517. 10.1038/nrneurol.2011.121.CrossRefPubMed
4.
Koller H, Kieseier BC, Jander S, Hartung HP: Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005, 352 (13): 1343-1356. 10.1056/NEJMra041347.CrossRefPubMed
5.
Said G: Chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord. 2006, 16 (5): 293-303. 10.1016/j.nmd.2006.02.008.CrossRefPubMed
6.
Anthoney DA, Bone I, Evans TR: Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2000, 11 (9): 1197-1200. 10.1023/A:1008362714023.CrossRef
7.
Bird SJ, Brown MJ, Shy ME, Scherer SS: Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology. 1996, 46 (3): 822-824. 10.1212/WNL.46.3.822.CrossRefPubMed
8.
Briemberg HR, Amato AA: Inflammatory neuropathies. Curr Neurol Neurosci Rep. 2005, 5 (1): 66-71. 10.1007/s11910-005-0026-z.CrossRefPubMed
9.
Zeng XL, Nagavalli A, Smith CJ, Howard JF, Su MA: Divergent effects of T cell costimulation and inflammatory cytokine production on autoimmune peripheral neuropathy provoked by Aire deficiency. Journal of immunology. 2013, 190 (8): 3895-3904. 10.4049/jimmunol.1203001.CrossRef
10.
van Schaik IN, Vermeulen M, van Doorn PA, Brand A: Anti-GM1 antibodies in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg). J Neuroimmunol. 1994, 54 (1–2): 109-115.CrossRefPubMed
11.
Feeney DJ, Pollard JD, McLeod JG, Stewart GJ, Doran TJ: HLA antigens in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1990, 53 (2): 170-172. 10.1136/jnnp.53.2.170.CrossRefPubMedPubMedCentral
12.
van Doorn PA, Schreuder GM, Vermeulen M, D’Amaro J, Brand A: HLA antigens in patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1991, 32 (2): 133-139. 10.1016/0165-5728(91)90005-R.CrossRefPubMed
13.
Czaplinski A, Steck AJ: Immune mediated neuropathies–an update on therapeutic strategies. J Neurol. 2004, 251 (2): 127-137. 10.1007/s00415-004-0323-5.CrossRefPubMed
14.
Kuitwaard K, van Doorn PA: Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy. Drugs. 2009, 69 (8): 987-1001. 10.2165/00003495-200969080-00004.CrossRefPubMed
15.
van Schaik IN, Winer JB, de Haan R, Vermeulen M: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol. 2002, 1 (8): 491-498. 10.1016/S1474-4422(02)00222-3.CrossRefPubMed
16.
Yoon MS, Chan A, Gold R: Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord. 2011, 4 (3): 193-200. 10.1177/1756285611405564.CrossRefPubMedPubMedCentral
17.
Robertson EE, Donofrio PD: Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol. 2010, 12 (2): 84-94. 10.1007/s11940-010-0058-9.CrossRefPubMed
18.
Group RMCT: Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 2009, 8 (2): 158-164.CrossRef
19.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Controlled clinical trials. 1986, 7 (3): 177-188. 10.1016/0197-2456(86)90046-2.CrossRefPubMed
20.
Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, Maurer SL, Riester K, Davar G, Dawson K, et al: Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2010, 74 (8): 651-657. 10.1212/WNL.0b013e3181d1a862.CrossRefPubMed
21.
Hermans G, Clerckx B, Vanhullebusch T, Segers J, Vanpee G, Robbeets C, Casaer MP, Wouters P, Gosselink R, Van Den Berghe G: Interobserver agreement of Medical Research Council sum-score and handgrip strength in the intensive care unit. Muscle Nerve. 2012, 45 (1): 18-25. 10.1002/mus.22219.CrossRefPubMed
22.
Zinman LH, Sutton D, Ng E, Nwe P, Ngo M, Bril V: A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfus Apher Sci. 2005, 33 (3): 317-324. 10.1016/j.transci.2005.07.010.CrossRefPubMed
23.
Bril V, Tomioka S, Buchanan RA, Perkins BA: Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabetic medicine: a journal of the British Diabetic Association. 2009, 26 (3): 240-246. 10.1111/j.1464-5491.2009.02667.x.CrossRef
24.
Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N: Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain. 2001, 124 (Pt 1): 145-153.CrossRefPubMed
25.
Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993, 56 (1): 36-39. 10.1136/jnnp.56.1.36.CrossRefPubMedPubMedCentral
26.
Bamford JM, Sandercock PA, Warlow CP, Slattery J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke; a journal of cerebral circulation. 1989, 20 (6): 828-10.1161/01.STR.20.6.828.CrossRefPubMed
27.
Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, Hartung HP, Hughes RA, Merkies IS, van Doorn PA: Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010, 67 (7): 802-807. 10.1001/archneurol.2010.105.CrossRefPubMed
28.
Merkies IS, Schmitz PI: Getting closer to patients: the INCAT overall disability sum score relates better to patients’ own clinical judgement in immune-mediated polyneuropathies. J Neurol Neurosurg Psychiatry. 2006, 77 (8): 970-972. 10.1136/jnnp.2005.076174.CrossRefPubMedPubMedCentral
29.
Kuitwaard K, van den Berg LH, Vermeulen M, Brusse E, Cats EA, van der Kooi AJ, Notermans NC, van der Pol WL, van Schaik IN, van Nes SI, et al: Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2010, 81 (12): 1374-1379. 10.1136/jnnp.2010.206599.CrossRefPubMed
30.
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004, 350 (25): 2572-2581. 10.1056/NEJMoa032534.CrossRefPubMed
31.
Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B: Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009, 65 (3): 286-293. 10.1002/ana.21577.CrossRefPubMed
32.
Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN: Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology. 2012, 78 (14): 1079-1084. 10.1212/WNL.0b013e31824e8f84.CrossRefPubMed
33.
Collen FM, Wade DT, Robb GF, Bradshaw CM: The Rivermead mobility index: a further development of the Rivermead motor assessment. International disability studies. 1991, 13 (2): 50-54. 10.3109/03790799109166684.CrossRefPubMed
34.
van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, Faber CG, van Oostrom JC, Vogels OJ, Hadden RD, et al: Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010, 9 (3): 245-253. 10.1016/S1474-4422(10)70021-1.CrossRefPubMed
35.
Mehndiratta MM, Hughes RA, Agarwal P: Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2004, 3: CD003906
36.
Dyck PJ, Daube J, O’Brien P, Pineda A, Low PA, Windebank AJ, Swanson C: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986, 314 (8): 461-465. 10.1056/NEJM198602203140801.CrossRefPubMed
37.
Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996, 119 (4): 1055-1066. 10.1093/brain/119.4.1055.CrossRefPubMed
38.
Lam J, Wulff H: The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression. Drug development research. 2011, 72 (7): 573-584. 10.1002/ddr.20467.CrossRefPubMedPubMedCentral
39.
Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG: The voltage-gated Kv1.3 K + channel in effector memory T cells as new target for MS. J Clin Invest. 2003, 111 (11): 1703-1713. 10.1172/JCI16921.CrossRefPubMedPubMedCentral
40.
Remenyi P, Masszi T, Borbenyi Z, Soos J, Siklos L, Engelhardt JI: CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur J Neurol. 2007, 14 (8): e1-e2. 10.1111/j.1468-1331.2007.01615.x.CrossRefPubMed
Metadata
Title
Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review
Authors
Richard J Bright
Jenny Wilkinson
Brendon J Coventry
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2014
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-14-26

Other articles of this Issue 1/2014

BMC Neurology 1/2014 Go to the issue

Research article

Mobilization after thrombolysis (rtPA) within 24 hours of acute stroke: what factors influence inclusion of patients in A Very Early Rehabilitation Trial (AVERT)?

Research article

Effects of differences in serum total homocysteine, folate, and vitamin B12on cognitive impairment in stroke patients

Research article

Predictors and long-term outcome of seizures in human immuno-deficiency virus (HIV)-negative cryptococcal meningitis

Research article

The brain structural and cognitive basis of odor identification deficits in mild cognitive impairment and Alzheimer's disease

Research article

The sense-of-coherence predicts health-related quality of life and emotional distress but not disability in Parkinson’s disease

Study protocol

Emergence and evolution of social self-management of Parkinson’s disease: study protocol for a 3-year prospective cohort study